Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Drug Delivery
Filter     Order     Display # 
Date Item Title
23 May 2006 New River Pharmaceuticals Initiates Pivotal Phase III Trial of NRP104 for Adult ADHD
23 May 2006 ALZA Corporation Receives FDA Approval for IONSYS(TM) (Fentanyl Iontophoretic Transdermal System)
23 May 2006 SkyePharma to develop improved controlled release version of Sular for first horizon
23 May 2006 ProEthic Pharmaceuticals Initiates Pivotal Phase III Trial for Fast-Acting Migraine Product Candidate; Trial to be conducted under Special Protocol Assessment
23 May 2006 BioDelivery Sciences Demonstrates Multiple Dose Linearity with BEMA(TM) Fentanyl; Another Development Milestone is Achieved in BDSI's Phase III BEMA(TM) Fentanyl Program
22 May 2006 FDA Grants Fast Track Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for Prevention of Pulmonary Fungal Infections in At-Risk Patients; First Inhaled Anti-Fungal Therapy Under Development for Immunosuppressed Patients
22 May 2006 XenoPort Reports Positive Preliminary Results from a Phase 2a Clinical Trial of XP19986 as a Treatment for Gastroesophageal Reflux Disease
22 May 2006 Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
20 May 2006 Yakult Honsha, Terumo to Co-develop Liposomal Formulation of Irinotecan
20 May 2006 Flamel Technologies Announces Receipt of Milestone from GlaxoSmithKline
17 May 2006 Boehringer Ingelheim signs a licence agreement with XstalBio for its protein formulation and drug delivery technology
16 May 2006 BioAlliance Pharma Starts Pivotal Phase III Clinical Trial in the US of Loramyc(R) Treatment for Oropharyngeal Candidiasis
15 May 2006 New Prescription Pain Treatment Completes European Mutual Recognition Procedure
10 May 2006 Eisai and Nitto Denko Sign a Joint Development Agreement on a Transdermal Patch Formulation of Aricept
09 May 2006 Alnylam Obtains Rights to RNAi Delivery Technology from The CBR Institute; Delivery Technology to Extend Alnylam's Leading Platform for RNAi Therapeutics
08 May 2006 Phosphagenics initiates Phase 2a clinical trial of its transdermal morphine cream
05 May 2006 VIVUS Announces Positive Phase 3 Clinical Trial Results for Evamist(TM) - The First Transdermal Spray for the Treatment of Menopausal Symptoms
05 May 2006 Javelin's Positive Rylomine(TM) Phase II Clinical Trial Data Presented at The American Pain Society Annual Meeting
05 May 2006 XenoPort Announces Presentation of XP13512 Data at the American Pain Society Meeting
04 May 2006 Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
03 May 2006 Abeille Pharmaceuticals In-Licenses Worldwide Exclusive Rights to Technology for Transdermal Patch Applications
02 May 2006 Clinician Presents Generex Oral-lyn(TM) Clinical Data at the Pediatric Academic Societies' 2006 Annual Meeting
02 May 2006 Javelin Announces Initial Results of a Pilot Phase II Study Of Intranasal Ketamine In Postoperative Orthopedic Pain
02 May 2006 Emisphere to Receive Milestone Payment for eligen(R) Technology to Be Used in New Development Program
29 Apr 2006 Aradigm Announces Update by Novo Nordisk on AERx Inhaled Insulin Phase 3 Clinical Program
28 Apr 2006 SkyePharma Announces First European Approval of DepoDur(TM)
28 Apr 2006 Pharmacokinetic Data for Nastech's Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile to Approved Injectable Product
27 Apr 2006 DURECT Provides An Update On Its Post-Operative Pain Depot (SABER™-Bupivacaine) Program
27 Apr 2006 A.P. Pharma Initiates APF530 Phase 3 Clinical Trial; IRB Approval Received
27 Apr 2006 Alexza Initiates AZ-003 Phase I Clinical Trial
27 Apr 2006 Lilly and Alkermes Initiate Additional Phase 3 Study for Inhaled Insulin as Part of Comprehensive Registration Program
24 Apr 2006 Antares Pharma Announces New Proprietary Dermatological Drug Delivery System
24 Apr 2006 BioDelivery Sciences Confirms Dose Proportionality with BEMA(TM) Fentanyl
21 Apr 2006 Camurus starts phase I clinical trial with CAM2029 – a new long-acting octreotide depot
20 Apr 2006 Alexza Initiates AZ-002 Phase IIa Clinical Trial in Patients With Panic Disorder
19 Apr 2006 Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss
18 Apr 2006 SurModics Licenses Hydrophilic Coating for the Devax AXXESS(TM) Drug-Eluting Bifurcation Stent Delivery System
13 Apr 2006 Emisphere Provides Update on Use of the eligen(R) Technology to Enhance Pulmonary Delivery of Proteins, Including Insulin
13 Apr 2006 MicroIslet Announces Encouraging Data From Islet Transplantation Studies in Primates
12 Apr 2006 Labopharm Reports Positive Results for Phase III Study on Once-Daily Tramadol
12 Apr 2006 Emisphere Completes Enrollment for Phase II Oral Insulin Clinical Trial
07 Apr 2006 Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD
07 Apr 2006 SCHWARZ PHARMA Presents Clinical Data on Rotigotine Transdermal Patch
06 Apr 2006 Dermisonics, Inc. Recruits Patients to Proceed With Human Pilot Trial-2 on U-Strip(TM) Ultrasonic Insulin Delivery System for Type-2 Diabetics
05 Apr 2006 ADVENTRX Presents Positive ANX-530 Preclinical Results
04 Apr 2006 LAB International completes patient enrollment in Fentanyl TAIFUN(R) Phase IIa trial
03 Apr 2006 Retisert slows progression of Diabetic Retinopathy in Diabetic Macular Edema trials
01 Apr 2006 Emisphere Reports Results of Study Comparing its Oral Heparin Formulation to Traditional Injectable Heparin
31 Mar 2006 Lipocine Reports Successful Clinical Results with a Fast-Acting Once-a-day Pain Management Product
30 Mar 2006 Bionutrics Announces the Initiation of Its Second US Development for a Generic Oral Controlled-Release Drug
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
Results 301 - 350 of 411

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics